Enrollment in Medicare is associated with fewer outpatient mental healthcare visits among those with mental health symptoms.

Objective: To test whether enrolling in traditional Medicare (TM) or Medicare Advantage (MA) at age 65 reduces mental healthcare utilization among individuals with mental health symptoms and low or moderate family incomes.

Study Setting And Design: We employ a fuzzy regression discontinuity design, comparing the likelihood of having an outpatient mental health visit or a psychotropic drug fill among individuals younger than or older than the age 65 Medicare eligibility threshold.

Data Sources And Analytic Sample: We analyze 2014-2021 Medical Expenditure Panel Survey data.

Recent cohorts aging into Medicare use more counseling and psychotherapy than past cohorts.

Objectives: Despite recent policy interest in improving access to mental health care in Medicare, little is known about how demand for care will change among the Medicare population as newer cohorts age into the program. We documented the growing rate of counseling and psychotherapy use in the decade prior to turning age 65 years among subsequent cohorts aging into Medicare. We characterized how this growth varied across demographic groups, income levels, and mental and physical health status.

Non-classical measurement error in instrumental variables estimation: An application to the medical care costs of obesity.

Estimates of the impact of body mass index and obesity on health and labor market outcomes often use instrumental variables estimation (IV) to mitigate bias due to endogeneity. When these studies rely on survey data that include self- or proxy-reported height and weight, there is non-classical measurement error due to the tendency of individuals to under-report their own weight. Mean reverting errors in weight do not cause IV to be asymptotically biased per se, but may result in bias if instruments are correlated with additive error in weight.

Real-World Data on Tezepelumab in Patients With Severe Asthma in Germany.

Background: Tezepelumab is a novel biologic blocking thymic stromal lymphopoetin, approved for severe asthma irrespective of biomarker levels or phenotype.

Objective: To characterize a real-world tezepelumab patient cohort and the efficacy among various asthma phenotypes.

Methods: We performed a retrospective, multicenter study on patients with severe asthma initiating tezepelumab.